The overall ratings of 5 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Cepheid (CPHD) is having a tough week. The company’s rating falls from a C to a D. Cepheid is a molecular diagnostics company that engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of CPHD stock.
This week, Achillion Pharmaceuticals, Inc.’s (ACHN) rating worsens to a D from the company’s C rating a week ago. Achillion Pharmaceuticals, Inc. focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of ACHN stock.
Slipping from a C to a D rating, Tenax Therapeutics, Inc. (TENX) takes a hit this week. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TENX stock.
MediciNova, Inc. (MNOV) declines this week from a C to a D. MediciNova, Inc. acquires, develops, and commercializes small molecule therapeutics. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MNOV stock.
This week, Immune Pharmaceuticals, Inc. (IMNP) drops from a D to a F rating. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMNP stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
